On March 19, Qingdao held a city-wide symposium to promote the high-quality development of the private economy. After the meeting, Tang Suyang, founder and chairman of Huaxia (Qingdao) Biotechnology Co., Ltd., said in an interview with Fengkou Finance that this conference has injected strong momentum into the development of private enterprises. Huaxia Biotechnology will take this as an opportunity to further strengthen its confidence, increase investment in technological innovation and product research and development, and promote the high-quality development of the enterprise.

Huaxia Biology made significant progress in 2024, as the company overcame the technology for the efficient and non-destructive preparation of decellularized matrix materials using supercritical carbon dioxide fluid. Currently, two third-class medical device products based on decellularized amniotic membrane have been developed. Tang Suyang said that among them, the facial product has steadily entered the final stage of registration clinical trials, and the clinical trials for the osteoarthritis product are also proceeding smoothly. According to the plan, the company will submit product registration documents by the end of 2025 and is expected to officially obtain the product registration certificate by the end of 2026.

Since its establishment, Huaxia Biology has been highly recognized by the industry in terms of technological innovation, clinical value, and market potential. It has won numerous awards in various authoritative competitions and was selected as one of the "Top 10 Innovative Seeds in Medical Devices for 2024" by the Qipu Award, a prestigious innovation award in the healthcare sector.

She stated that this year, Huaxia Biology will go all out to steadily advance the clinical and registration work of two products, accelerating their early market launch in the country. In addition, Huaxia Biology will also initiate the research and development of new product pipelines and join hands with the Rehabilitation University to accelerate the construction of a digital and intelligent perinatal tissue material bank. By expanding in-depth cooperation with scientific research institutions and medical institutions, it will strengthen the company's scientific research capabilities, optimize the industrial chain layout, and lay a solid foundation for the company's long-term development.

Full of confidence, the company will continue to delve deeply into the field of biomedical materials, striving to become a global leader in the research and development application of human-derived tissue regeneration materials, contributing to the high-quality development of the large health industry.